Sab-142

Phase 3

UUniversity of Florida

Sab-142 is one of 3 therapeutic programs targeting Type 1 Diabetes (T1D). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 1 Diabetes (T1D)Not yet recruiting

Type 1 Diabetes (T1D)Phase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Type 1 Diabetes (T1D)

#DrugCompanyPhaseTrials

Simponi

Johnson & Johnson

Phase 2

1 2

AMX0035

AAmylyx Pharmaceuticals Inc.

Phase 2

1 3

Sab-142

UUniversity of Florida

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Not yet recruiting

Type 1 Diabetes (T1D)

NCT07670650

Clinical

Trials by Indication[1]

Type 1 Diabetes (T1D)1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset T1D, Recent Onset T1D, and Established T1D

Not yet recruiting·UUniversity of Florida·Phase 3·NCT07670650·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sab-142. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sab-142. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Florida

Sab-142

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Type 1 Diabetes (T1D)1 trial

References

Drug Info

Quick Facts

Related News